BioNxt Solutions Advances MS Drug Program
Company Announcements

BioNxt Solutions Advances MS Drug Program

Story Highlights

BioNxt Solutions (TSE:BNXT) has released an update.

BioNxt Solutions Inc. announces significant progress in its sublingual Cladribine program for Multiple Sclerosis treatment, highlighting its potential advantage for patients with difficulty swallowing. The company has reported positive results from preclinical studies and plans a human bioequivalence study in early Q1 2025. Additionally, a comprehensive patent application for sublingual anticancer drugs has received a positive international examination report by the EPO.

For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Advances Patent Process for New Drugs
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Expands Patent Protection Globally
TipRanks Canadian Auto-Generated NewsdeskBioNxt Solutions Welcomes New Capital Markets Advisor
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App